Natural Alternatives International, Inc. — FY2014 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended June 30, 2014, compared with FY2013; it is not a report for calendar 2013 Q4. NAI manufactures private-label nutritional supplements and earns licensing revenue from its CarnoSyn beta-alanine patent estate. It also sold Pathway to Healing branded products, but decided to wind down that line. Financial statements are consolidated with its Swiss subsidiary, NAIE.
Financial performance
| Metric | FY2014 | FY2013 | Change |
|---|---|---|---|
| Net sales | $73.94 million | $62.80 million | +17.7% |
| Gross profit / margin | $12.74 million / 17.2% | $12.14 million / 19.3% | Margin down 2.1 percentage points |
| Operating income / margin | $2.78 million / 3.8% | $2.15 million / 3.4% | +29% |
| Net income / diluted EPS | $1.99 million / $0.29 | $1.57 million / $0.23 | Net income +27% |
| Operating cash flow | $5.35 million | $4.47 million | +20% |
| Capital expenditures | $2.68 million | $1.62 million | Higher investment |
- Private-label manufacturing sales rose 18.8% to $67.34 million, mainly on higher volumes, new products, and sales to new customers. Patent and trademark licensing sales rose 13.4% to $5.44 million. Branded-product sales fell 12.6% to $1.16 million.
- Gross margin weakened primarily because of sales mix, lower average selling prices, higher manufacturing costs, and branded-product inventory write-downs. The FY2014 write-down included about $320,000 associated with discontinuing Pathway to Healing.
- Cash and cash equivalents were $19.51 million at year-end, versus $16.70 million. Working capital was $31.30 million. The company reported no outstanding debt and $5.6 million available under credit facilities; its $5 million Wells Fargo line was undrawn. Management said available resources should cover working capital and capital expenditures for at least 12 months.
- Inventory increased to $12.84 million from $10.04 million, using $2.81 million of operating cash. Accounts payable and accrued liabilities provided $3.11 million of operating cash. Investing activities used $2.47 million; financing activities used $0.06 million.
Material changes, outlook, and risks
- Revenue concentration remains substantial: NSA represented 38% of private-label sales, Mannatech 17%, and Shaklee 16%. The top two customers together accounted for 55% of manufacturing sales, down from 69% in FY2013. NSA’s agreements expired April 1, 2014; NAI continued fulfilling monthly orders while negotiating renewal and expansion terms.
- Abbott terminated its exclusive beta-alanine license and supply agreement effective November 27, 2013. NAI reported $5.1 million of royalty income in FY2014 and expects licensing and related revenue to expand in FY2015, subject to patent protection, supply availability, and third-party compliance. Its CSI agreement was due to expire March 31, 2015.
- Management anticipated positive net income in FY2015, but gave no specific earnings or revenue forecast. Priorities include gaining manufacturing customers, expanding beta-alanine licensing, and improving efficiency and cost management.
- Management expects raw-material availability and pricing pressures, including higher labor and transportation costs, to continue in FY2015. Other material risks include dependence on major customers and suppliers, order timing, regulatory compliance, product liability, foreign exchange, and the highly competitive supplement market.
- NAI incurred about $2.2 million of patent litigation and compliance expense in FY2014 and estimated FY2015 expense of $500,000–$1.0 million. A DNP dispute settled in July 2014, with DNP agreeing to exit beta-alanine. Patent litigation with Woodbolt remained pending; the USPTO had rejected claims of two challenged patents, with NAI pursuing an appeal on one and the other rejection issued in August 2014. Several product-liability claims against NAI were dismissed with prejudice during FY2014.
- Pathway to Healing license termination took effect September 15, 2014, after year-end; wind-down was expected to finish by the end of FY2015’s second quarter. NAI did not present the segment as discontinued operations.
- The independent auditor gave an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal-control effectiveness.
Investor verification priorities
- Check whether NSA agreements were renewed and how customer concentration and order volumes subsequently changed.
- Assess the sustainability of CarnoSyn royalties, CSI contract terms, beta-alanine supply, and the outcome and costs of patent proceedings.
- Track gross margin recovery, inventory growth and reserves, and whether higher input costs can be offset by pricing or efficiency gains.
- Confirm FY2015 results against management’s expectation of positive net income and continued licensing growth.
- Review liquidity access and covenant compliance, including the credit line’s November 2015 maturity and cash held offshore that management considered indefinitely reinvested.